切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2020, Vol. 09 ›› Issue (05) : 440 -446. doi: 10.3877/cma.j.issn.2095-3224.2020.05.002

所属专题: 文献

专家论坛

直肠癌新辅助治疗后病理完全缓解的预测进展
邹雨恒1, 刘健博1, 汪晓东2, 李立2,()   
  1. 1. 610041 成都市,四川大学华西医院胃肠外科;610041 四川大学华西临床医学院
    2. 610041 成都市,四川大学华西医院胃肠外科
  • 收稿日期:2020-03-02 出版日期:2020-10-25
  • 通信作者: 李立
  • 基金资助:
    四川大学大学生创新创业计划项目(No. C2019107137)

A review of the prediction of pCR after neoadjuvant therapy for rectal cancer

Yuheng Zou1, Jianbo Liu1, Xiaodong Wang2, Li Li2,()   

  1. 1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China; West China School of Medicine in Sichuan University, Chengdu 610041, China
    2. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
  • Received:2020-03-02 Published:2020-10-25
  • Corresponding author: Li Li
  • About author:
    Corresponding author: Li Li, Email:
引用本文:

邹雨恒, 刘健博, 汪晓东, 李立. 直肠癌新辅助治疗后病理完全缓解的预测进展[J/OL]. 中华结直肠疾病电子杂志, 2020, 09(05): 440-446.

Yuheng Zou, Jianbo Liu, Xiaodong Wang, Li Li. A review of the prediction of pCR after neoadjuvant therapy for rectal cancer[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(05): 440-446.

目前血红蛋白(Hb),中性粒-淋巴细胞比例(NLR),癌胚抗原(CEA),缘距(DTAV),肿瘤长度(TL),临床TNM分期(cTNM),影像学检查手段(MRI,PET-CT,直肠内超声,肠镜),新辅助治疗参数(治疗方案,放疗剂量,新辅助治疗后和手术之间的时间间隙),基因/分子特征对病理完全缓解(pCR)的预测报道较多。相比较而言,患者特征中CEA,TL以及新辅助治疗方案的相关参数预测价值较为稳定且更有价值,MRI,PET-CT,内镜等检查手段也是评估pCR的重要方式,基因分子学特征方面的预测很有潜力,但仍需进一步更大的前瞻性研究。如何提供更为准确的判断,可以进一步通过多因素的因果模型,作为研究方向。

Hemoglobin (Hb), neutrophil-to-lymphocyte ratio (NLR), carcinoembryonic antigen (CEA), distance of tumor from the anal verge (DTAV), tumor length (TL), clinical TNM staging (cTNM), imaging examination measures (MRI, PET-CT, rectal ultrasound, enteroscopy), parameters of neoadjuvant therapy (protocol, radiotherapy dose, time interval between neoadjuvant treatment and surgery) and from genetic/molecular features have been reported to predict pathological complete response (pCR) recently. The predictive value of the CEA, TL, and relevant parameters of neoadjuvant therapy is more stable and valuable. Examination methods such as MRI, PET-CT, endoscopy are also important ways to evaluate pCR. Genetic molecular characteristics is promising predictors, but further and larger prospective studies are still required. How to provide more accurate judgment can be further through multi-factor causal models as research directions.

[1]
Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2018, 16(7): 874-901.
[2]
Du B, Wang X, Wu D, et al. MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer [J]. Mol Med Rep, 2018, 18(2): 1909-1916.
[3]
Kheirelseid EA, Miller N, Chang KH, et al. miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy [J]. Int J Colorectal Dis, 2013, 28(2): 247-260.
[4]
Martinez-Useros J, Moreno I, Fernandez-Acenero MJ, et al. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer [J]. BMC Cancer, 2018, 18(1): 144.
[5]
Peng H, You K, Zhang R, et al. Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma [J]. Oncotarget, 2016, 7(23): 35233-35240.
[6]
Kundel Y, Nasser NJ, Rath-Wolfson L, et al. Molecular predictors of response to neoadjuvant chemoradiation for rectal cancer [J]. Am J Clin Oncol, 2018, 41(6): 613-618.
[7]
Yu J, Lee SH, Jeung TS, et al. Expression of vascular endothelial growth factor as a predictor of complete response for preoperative chemoradiotherapy in rectal cancer [J]. Medicine (Baltimore), 2019, 98(26): e16190.
[8]
Nelson B, Carter JV, Eichenberger MR, et al. Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer [J]. Surgery, 2016, 160(5): 1326-1332.
[9]
Chow OS, Kuk D, Keskin M, et al. KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy [J]. Ann Surg Oncol, 2016, 23(8): 2548-2555.
[10]
Hasegawa S.,Goto S, Matsumoto T, et al. A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer [J]. Ann Surg Oncol, 2017, 24(12): 3587-3595.
[11]
Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study [J]. Int J Colorectal Dis, 2012, 27(10): 1325-1332.
[12]
Sebio A, Salazar J, Paez D, et al. EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer [J]. Pharmacogenomics J, 2015, 15(1): 77-83.
[13]
Hodek M, Sirak I, Ferko A, et al. Neoadjuvant chemoradiotherapy of rectal carcinoma : Baseline hematologic parameters influencing outcomes [J]. Strahlenther Onkol, 2016, 192(9): 632-640.
[14]
Runau F, Collins A, Fenech GA, et al. A single institution's long-term follow-up of patients with pathological complete response in locally advanced rectal adenocarcinoma following neoadjuvant chemoradiotherapy [J]. Int J Colorectal Dis, 2017, 32(3): 341-348.
[15]
Krauthamer M, Rouvinov K, Ariad S, et al. A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer [J]. Oncology, 2013, 85(1): 27-32.
[16]
van der Sluis FJ, van Westreenen HL, van Etten B, et al. Pretreatment identification of patients likely to have pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer [J]. Int J Colorectal Dis, 2018, 33(2): 149-157.
[17]
Peng J, Lin J, Qiu M, et al. Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer [J]. Clinics (Sao Paulo, Brazil), 2016, 71(8): 449-454.
[18]
Kim TG, Park W, Kim H, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy [J]. Tumori, 2019, 105(5): 434-440.
[19]
Lee SY, Kim CH, Kim YJ, et al. Obesity as an independent predictive factor for pathologic complete response after neoadjuvant chemoradiation in rectal cancer [J]. Ann Surg Treat Res, 2019, 96(3): 116-122.
[20]
Wallin U, Rothenberger D, Lowry A, et al. CEA-a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer [J]. Dis Colon Rectum, 2013, 56(7): 859-868.
[21]
Li A, He K, Guo D, et al. Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer [J]. Future Oncology (London, England), 2019, 15(28): 3233-3242.
[22]
KaladyMF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer [J]. Ann Surg, 2009, 250(4): 582-589.
[23]
Hu H, Huang J, Lan P, et al. CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial [J]. BMC cancer, 2018, 18(1): 1145.
[24]
Alexander JC, Silverman NA, Chretien PB. Effect of age and cigarette smoking on carcinoembryonic antigen levels [J]. JAMA, 1976, 235(18): 1975-1979.
[25]
Ren DL, Li J, Yu HC, et al. Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer [J]. World J Gastroenterol, 2019, 25(1): 118-137.
[26]
Song J, Huang X, Chen Z, et al. Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0-I after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. Cancer Manag Res, 2018, 10: 3101-3108.
[27]
Peng H, Wang C, Xiao W, et al. Analysis of clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy [J]. Journal of Cancer, 2018, 9(15): 2687-2692.
[28]
Patel SV, Roxburgh CS, Vakiani E, et al. Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer [J]. J Surg Oncol, 2016, 114(5): 637-641.
[29]
van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging [J]. Radiother Oncol, 2011, 98(1): 126-133.
[30]
De Felice F, Izzo L, Musio D, et al. Clinical predictive factors of pathologic complete response in locally advanced rectal cancer [J]. Oncotarget, 2016, 7(22): 33374-33380.
[31]
Griethuysen JJMV, Lambregts DMJ, Trebeschi S, et al. Radiomics performs comparable to morphologic assessment by expert radiologists for prediction of response to neoadjuvant chemoradiotherapy on baseline staging MRI in rectal cancer [J]. Abdom Radiol (NY), 2020, 45(3): 632-643.
[32]
Napoletano M, Mazzucca D, Prosperi E, et al. Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging in restaging after neoadjuvant chemo-radiotherapy [J]. Abdom Radiol (NY), 2019, 44(11): 3664-3673.
[33]
Choi MH, Oh SN, Rha SE, et al. Diffusion-weighted imaging: Apparent diffusion coefficient histogram analysis for detecting pathologic complete response to chemoradiotherapy in locally advanced rectal cancer [J]. J Magn Reson Imaging: JMRI, 2016, 44(1): 212-220.
[34]
De Felice F, Magnante AL, Musio D, et al. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy [J]. Euro J Surg Oncol: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, 43(7): 1324-1329.
[35]
Koo PJ, Kim SJ, Chang S, et al. Interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography to predict pathologic response to preoperative chemoradiotherapy and prognosis in patients with locally advanced rectal cancer [J]. Clin Colorectal Cancer, 2016, 15(4): e213-e219.
[36]
Park J, Chang KJ, Seo YS, et al. Tumor SUVmax normalized to liver uptake on (18)F-FDG PET/CT predicts the pathologic complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. Nuclear Medicine and Molecular Imaging, 2014, 48(4): 295-302.
[37]
van der Sande ME, Maas M, Melenhorst J, et al. Predictive value of endoscopic features for a complete response after chemoradiotherapy for rectal cancer [J]. Ann Surg, 2019.
[38]
Kawai K, Ishihara S, Nozawa H, et al. Prediction of pathological complete response using endoscopic findings and outcomes of patients who underwent watchful waiting after chemoradiotherapy for rectal cancer [J]. Dis Colon Rectum, 2017, 60(4): 368-375.
[39]
Liu S, Zhong GX, Zhou WX, et al. Can endorectal ultrasound, mri, and mucosa integrity accurately predict the complete response for mid-low rectal cancer after preoperative chemoradiation? A prospective observational study from a single medical center [J]. Dis Colon Rectum, 2018, 61(8): 903-910.
[40]
Li N, Dou L, Zhang Y, et al. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer [J]. Gastrointest Endosc, 2017, 85(3): 669-674.
[41]
Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial [J]. J Clin Oncol, 2016, 34(27): 3300-3307.
[42]
Hall MD, Schultheiss TE, Smith DD, et al. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy [J]. Acta Oncol, 2016, 55(12): 1392-1399.
[43]
Al-Sukhni E, Attwood K, Mattson DM, et al. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer [J]. Ann Surg Oncol, 2016, 23(4): 1177-1186.
[44]
Wiltshire KL, Ward IG, Swallow C, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival [J]. International J of Radiat Oncol Biol, Physics, 2006, 64(3): 709-716.
[45]
Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study [J]. Ann Oncol, 2016, 27(5): 834-842.
[46]
Lee SW, Lee JH, Lee IK, et al. The impact of surgical timing on pathologic tumor response after short course and long course preoperative chemoradiation for locally advanced rectal adenocarcinoma [J]. Cancer Res Treat: Official Journal of Korean Cancer Association, 2018, 50(3): 1039-1050.
[47]
Hoendervangers S, Couwenberg AM, Intven MPW, et al. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer [J]. Euro J Surg Oncol: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, 44(7): 1013-1017.
[48]
Choi E, Kim JH, Kim OB, et al. Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience [J]. Radiat Oncol J, 2016, 34(2): 106-112.
[49]
Zeng WG, Liang JW, Wang Z, et al. Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer [J]. Chin J Cancer, 2015, 34(10): 468-474.
[50]
Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: A multicenter, randomized, controlled trial (GRECCAR-6) [J]. J Clin Oncol, 2016, 34(31): 3773-3780.
[1] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[2] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[3] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[4] 奚玲, 仝瀚文, 缪骥, 毛永欢, 沈晓菲, 杜峻峰, 刘晔. 基于肌少症构建的造口旁疝危险因素预测模型[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 48-51.
[5] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 郑民华, 蒋天宇, 赵轩, 马君俊. 中国腹腔镜直肠癌根治术30年发展历程与未来[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 591-595.
[8] 池畔, 黄胜辉. 中国腹腔镜直肠癌根治术30年来的巨大进步[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 596-600.
[9] 李明, 屠松, 闫鹏, 钱军, 高鹏程, 许文山, 杨发英, 胡振涛, 单永玮. 应用前列腺电切镜引导置管治疗直肠低位吻合口漏研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 603-606.
[10] 李玲, 刘亚, 李培玲, 张秀敏, 李萍. 直肠癌患者术后肠道菌群的变化与抑郁症相关性研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 607-610.
[11] 赵梓竣, 兰运升. 改良一针法末端回肠造口术对低位直肠癌保肛术后应激反应及安全性的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 611-614.
[12] 韦巧玲, 黄妍, 赵昌, 宋庆峰, 陈祖毅, 黄莹, 蒙嫦, 黄靖. 肝癌微波消融术后中重度疼痛风险预测列线图模型构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 715-721.
[13] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
阅读次数
全文


摘要